Fouad A Siddiqi

US Patent:

7470517, Dec 30, 2008

Filed:

Apr 8, 2005

Appl. No.:

11/547765

Inventors:

Charles R. Cantor - Del Mar CA, US
Fouad A. Siddiqi - Boston MA, US

Assignee:

Trustees of Boston University - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known sequences. The identities of these sequences are determined solely by the specific fragmentation method used, and are always independent of the target. PSBF can be implemented using electrophoresis, mass spectrometry or any other method that can be used to distinguish the size of the cut nucleic acid sequence fragments.

US Patent:

7807375, Oct 5, 2010

Filed:

Oct 28, 2008

Appl. No.:

12/259376

Inventors:

Charles R Cantor - Del Mar CA, US
Fouad A Siddiqi - Boston MA, US

Assignee:

Trustees of Boston University - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known sequences. The identities of these sequences are determined solely by the specific fragmentation method used, and are always independent of the target. PSBF can be implemented using electrophoresis, mass spectrometry or any other method that can be used to distinguish the size of the cut nucleic acid sequence fragments.

US Patent:

20020045178, Apr 18, 2002

Filed:

Jun 13, 2001

Appl. No.:

09/880988

Inventors:

Charles Cantor - Del Mar CA, US
Fouad Siddiqi - Boston MA, US

Assignee:

The Trustees of Boston University

International Classification:

C12Q001/68
G06F019/00
G01N033/48
C12P019/34

US Classification:

435/006000, 435/091200, 702/020000

Abstract:

Methods and kits that use nucleotide analogs to confer increased accuracy and improved resolution in the analysis and sequencing of oligonucleotide mixtures are provided.

US Patent:

20090312358, Dec 17, 2009

Filed:

Mar 22, 2007

Appl. No.:

12/294003

Inventors:

Fouad A. Siddiqi - Brookline MA, US

Assignee:

TRUSTEES OF BOSTON UNIVERSITY - Boston MA

International Classification:

A61K 31/485
A61K 31/445
A61K 31/451
A61K 31/222
A61P 1/12

US Classification:

514282, 514317, 514327, 514330, 514331, 514513

Abstract:

The present invention is directed to methods of treatment and/or management of diarrhea, such as chronic diarrhea using sequential administration of opioid agonists to suppress gut mobility and opioid antagonists to reverse the effect to controllably allow bowel movements. The agonists and antagonists are administered with a time interval in between the administration or between the release of the drugs from a pharmaceutical composition. The invention is further directed to methods of controlling, treating or managing side effects caused by the opioid agonists, specifically the side effects resulting from mast cell activation and/or granulation.